Wall Street brokerages forecast that Sensus Healthcare Inc (NASDAQ:SRTS) will post earnings of ($0.13) per share for the current fiscal quarter, Zacks reports. Three analysts have made estimates for Sensus Healthcare’s earnings, with the lowest EPS estimate coming in at ($0.15) and the highest estimate coming in at ($0.11). Sensus Healthcare reported earnings of ($0.04) per share in the same quarter last year, which would indicate a negative year-over-year growth rate of 225%. The firm is expected to report its next earnings results on Wednesday, November 4th.
On average, analysts expect that Sensus Healthcare will report full-year earnings of ($0.60) per share for the current year, with EPS estimates ranging from ($0.69) to ($0.52). For the next year, analysts anticipate that the company will post earnings of ($0.04) per share, with EPS estimates ranging from ($0.19) to $0.11. Zacks’ earnings per share calculations are a mean average based on a survey of research firms that cover Sensus Healthcare.
Sensus Healthcare (NASDAQ:SRTS) last announced its quarterly earnings data on Thursday, August 6th. The company reported ($0.16) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.18) by $0.02. Sensus Healthcare had a negative net margin of 34.01% and a negative return on equity of 23.08%. The company had revenue of $1.18 million during the quarter, compared to analyst estimates of $1.61 million.
Shares of NASDAQ:SRTS opened at $2.65 on Wednesday. The company has a market cap of $43.73 million, a PE ratio of -7.36 and a beta of 0.15. The company’s 50-day moving average price is $2.82 and its 200 day moving average price is $2.81. Sensus Healthcare has a fifty-two week low of $1.76 and a fifty-two week high of $6.48. The company has a quick ratio of 4.51, a current ratio of 5.65 and a debt-to-equity ratio of 0.04.
An institutional investor recently raised its position in Sensus Healthcare stock. Morgan Stanley increased its stake in shares of Sensus Healthcare Inc (NASDAQ:SRTS) by 12,595.0% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 12,695 shares of the company’s stock after purchasing an additional 12,595 shares during the quarter. Morgan Stanley owned approximately 0.08% of Sensus Healthcare worth $32,000 at the end of the most recent reporting period. Institutional investors own 8.34% of the company’s stock.
Sensus Healthcare Company Profile
Sensus Healthcare, Inc manufactures and markets superficial radiation therapy devices to healthcare providers worldwide. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates the embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters.
Read More: Liquidity
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Sensus Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sensus Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.